NDAINTRAVENOUSSOLUTION
Approved
Feb 2025
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE (epinephrine) by Baxter is (α)- and beta (β)-adrenergic receptors. Approved for septic shock, cardiac arrest, ventricular fibrillation and 1 more indications. First approved in 2025.
Drug data last refreshed 19h ago
Mechanism of Action
(α)- and beta (β)-adrenergic receptors. The mechanism of the rise in blood pressure is 3-fold: a direct myocardial stimulation that increases the strength of ventricular contraction (positive inotropic action), an increased heart rate (positive chronotropic action), and peripheral vasoconstriction.
Indications (4)
Worked on EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE at Baxter? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.